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Abstract Proinflammatory cytokines and growth factors,
which regulate mutual interactions between immune sys-
tem cells and bone tissue cells, play a major role in the
formation of bone changes in rheumatoid arthritis (RA).
The aim of the work was to assess serum concentration of
osteoprotegerin (OPG), RANKL, Dkk-1 and sclerostin in
RA patients compared to a control group and to analyze
changes of these concentrations during methotrexate
(MTX) therapy. Patients enrolled in the study were 30
women of Caucasian origin aged 30–74 years with RA.
Patients with active form of the disease were administered
recommended doses of MTX for at least 6 months. The
study group was divided into subgroup I—patients with
improvement; and subgroup II—patients with no im-
provement. The control group consisted of 12 healthy
women in the age of 41–73. Before MTX therapy, RA
patients had higher levels of RANKL (644.97 ± 477.13 vs.
255.19 ± 130.26 pmol/l), lower values of OPG/RANKL
(0.01 ± 0.0101 vs. 0.02 ± 0.0078) and higher levels of
Dkk-1 protein (1821.32 ± 1060.28 vs. 548.52 ± 36.35 pg/
ml) compared to the control group. In the analyzed group
of patients (all patients receiving MTX regardless of re-
sponder non responder status) after 6 months of therapy, a
statistically significant increase in the ratio of OPG/
RANKL was found (0.0118 ± 0.0102 vs. 0.0141 ± 0.0118;
p = 0.02). The index value of OPG/RANKL differed sig-
nificantly depending on the resultant effect of treatment
(0.01702 ± 0.01274 in the subgroup of improvement vs.
0.00675 ± 0.00289 in the subgroup without improvement).
The difference in the mean concentrations of Dkk-1 before
and after treatment with MTX between subgroups I and II
was statistically significant (p = 0.002). In subgroup I,
mean concentration of Dkk-1 decreased after 6 months of
treatment with MTX (2054.72 ± 1004.74 vs. 1831.70 ±
851.70 pg/ml); while in subgroup II, the mean concentra-
tion of Dkk-1 increased (1214.48 ± 738.32 vs. 2275.01 ±
1385.23 pg/ml). There were no statistically significant
changes in the mean concentrations of sclerostin before and
after treatment with MTX (in whole group treatment with
MTX, in subgroup I, and in subgroup II). The results
confirm the presence of disorders of bone metabolism in
patients with RA. Treatment with MTX affects the value of
the ratio of OPG/RANKL and concentration of Dkk-1.
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Introduction
Rheumatoid arthritis (RA) is a chronic disease of autoim-
mune origin that, when improperly treated, causes
disability in most cases. It affects 1 % of adults, pre-
dominantly women. It is associated with synovial
inflammation with accompanying cartilage damage and
bone lesions (Scott et al. 2010). The radiological features
include periarticular osteopenia, erosions, joint space nar-
rowing and deformity such as subluxation and dislocation
(Brown 2013).
However, the mechanism of these lesions is not fully
understood. It has been demonstrated that there is a sig-
nificant role of proinflammatory cytokines and growth
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factors that regulate mutual interactions between immune
system cells and bone tissue cells: osteoclasts, osteoblasts
and osteocytes. Osteoclasts are responsible for bone re-
sorption and osteoblasts are responsible for the synthesis
and mineralization of bone (Neve et al. 2011).
Bone destruction is controlled by the complex interplay
between three molecules essential for bone biology: re-
ceptor activator of nuclear factor jB ligand (RANKL),
RANK and osteoprotegerin (OPG) (Revu et al. 2013;
Schett et al. 2005). The connection of RANKL with its
receptor RANK induces the process of formation of os-
teoclasts (proliferation, differentiation, functioning) and
inhibits osteoclast apoptosis (Kmiec´ and Sokołowska
2007; Vis et al. 2013). Mice with a disrupted RANKL
gene show severe osteopetrosis and completely lack os-
teoclasts (Kong et al. 1999). Catabolic effects of RANKL
are inhibited by OPG, thereby preventing the activation of
its receptor RANK (Danks and Takayanagil 2013; Sin-
ningen et al. 2012). During physiological bone remodeling,
the ratio of RANKL to OPG is balanced (Sinningen et al.
2012).
The Wnt/b-catenin pathway participates in the regula-
tion of osteoblasts. It affects the proliferation, maturation,
function and apoptosis of these cells (Krys´kiewicz and
Lorenc 2010). The presence of strong inhibitors of Wnt/b-
catenin protein [Dickkopf-1 (Dkk-1), sclerostin] results in
the inhibition of bone formation (Vis et al. 2013).
Methotrexate (MTX) is a first-line drug in RA (Smolen
et al. 2010). It is one of the disease-modifying anti-
rheumatoid drugs (DMARDs). It slows down articular
damage in RA patients (Kucharz 2011). MTX inhibits di-
hydrofolate reductase activity, thus blocking synthesis of
purine nucleotides and thymidylates, which are essential
for nucleic acid synthesis and repair, and cell replication
(Orzechowska-Juzwenko 2001). The question whether the
main mode of action of the drug is immunosuppressive,
immunomodulating, cytostatic or anti-inflammatory is still
being studied. One of the significant modes of MTX action
is its effect on inflammation inhibition through increase of
extracellular adenosine concentration.
Studies on animal models demonstrate that high doses of
MTX may damage bone progenitor cells and inhibit pro-
liferation of osteoblasts and intensify bone resorption (Fan
et al. 2011). Use of MTX in patients with malignancies was
associated with bone mass decrease and osteoporosis
(Stava et al. 2009). However, there still remain doubts
about the adverse effect of MTX on bone tissue metabo-
lism in RA. Much lower doses are used in these cases. Only
isolated papers on bone metabolism regulation changes in
RA patients are available in the literature.
In the active RA occurs the severity of bone resorption
and decrease bone formation. El Miedany et al. (1998)
observed after treatment with MTX reduction in bone
resorption which may be due to the reduction of disease
activity. Revu et al. (2013) observed that MTX decreased
synovial cellularity in RA. Changes in cellularity were
accompanied by decrease in local expression of RANKL
and the RANKL/OPG ratio. They did not observe change
in the expression of OPG (Revu et al. 2013).
The aim of the work was to assess serum concentration
of OPG, RANKL, Dkk-1 and sclerostin in RA patients
compared to a control group and to analyze changes of
these concentrations during MTX therapy and in relation to
achieved response to therapy.
Materials and Methods
Characteristics of Patients
Patients enrolled in the study were 30 women of Caucasian
origin aged 30–74 years with an established diagnosis of
RA according to American College of Rheumatology
(ACR) criteria. In connection with literature data showing
the differences in etiology of osteoporosis in men and
women (the influence of sex hormones, other growth rate
of bone loss, reaching another peak bone mass), only
women were enrolled in the study. Patients with active
form of the disease were administered recommended doses
of MTX for at least 6 months. The study group was divided
into subgroup I—patients with improvement, and subgroup
II—patients with no improvement.
Three patients were excluded from the analysis due to
irregular reporting to follow-up visits and incomplete data.
Twenty-seven women aged 30–74 years (mean 54.7 years,
SD s = 12.36, median xmed = 55) were qualified for the
final analysis. 73 % of women in the study group were
postmenopausal. Mean disease duration was 4.75 years—
in 59 % of the patients it was for 2 years. In 12 patients
(44 %), disease duration was 12 months; in 4 patients
(15 %), it was between 12 and 24 months; while in 11
patients (41 %), it was over 24 months. To determine the
severity of bone lesions according to the Steinbrocker
classification, patients underwent X-ray of hands (Stein-
brocker et al. 1949). In terms of severity of radiological
changes, the patients were divided into two groups: the first
comprising patients with stages I and II changes, the sec-
ond comprising patients with stages III and IV changes.
According to this classification, the first-stage RA is
characterized by synovitis, or an inflammation of the syn-
ovial membrane, causing swelling of involved joints and
pain upon motion. However, there is no X-ray evidence of
joint destruction, with the exception of swelling of soft
tissues or early stages of osteoporosis. In stage II, there is a
spread of inflammation in synovial tissue, affecting joint
cavity space across joint cartilage. This inflammation will
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gradually result in a destruction of cartilage, accompanied
by a narrowing of the joint. Severe RA, stage III, is marked
by the formation of pannus in the synovium. Loss of joint
cartilage exposes bone beneath the cartilage. These chan-
ges will become evident on X-ray, along with erosions and
signs of deformation. Stage IV is called terminal or end-
stage RA. The inflammatory process has subsided and
formation of fibrous tissue and/or fusing of bone results in
ceased joint function. Rheumatoid nodules may also be
present in patients in stage IV of the disease.
The following inclusion criteria were accepted: consent
to participate in the study; confirmed RA based on 1987
classification criteria of the ACR; active form of the dis-
ease—disease activity score based on erythrocyte
sedimentation rate and an evaluation of 28 joints
(DAS28) C 4.0 (26 of patients had DAS28[ 5.1); no use
of MTX during the last 1 year; age over 18 years.
There were the following exclusion criteria: pregnancy
or breastfeeding; coexistence of other systemic diseases of
connective tissue besides RA; clinically significant im-
pairment of hepatic and renal function; alcohol abuse;
infection with hepatotropic viruses; infections resistant to
therapy; ongoing history of cancer if no cure was achieved;
uncontrolled diabetes; patient unwilling or unable to co-
operate. Patients were administered with recommended
doses of MTX for at least 6 months. Patients were starting
therapy with 15 mg MTX once a week, and the dose could
be increased to 25 mg once weekly (mean dose 15.4 mg/
week). The patients were allowed to continue treatment
with other DMARDs, glucocorticoids, and/or non-steroidal
anti-inflammatory drugs, if the treatment regimens were
not modified 4 weeks before the study. Fifty-two percent of
patients used prednisone at a mean dose of 7.8 mg/day
(4–10 mg/day). Prednisone doses were constant for at least
8 weeks before the start of the study and during the study.
To examine the response to MTX therapy, blood sam-
ples, laboratory data, and clinical data were collected at
baseline (prior to MTX therapy), 2, 4 and 6 months post
treatment. Clinical evaluation was based on medical
history, number of painful and swollen joints, pain inten-
sity assessed by the patient on a 100-mm visual analog
scale and laboratory tests (ESR, CRP). The parameters
allowed determination of improvement according to the
criteria based on DAS28 suggested by the European Lea-
gue Against Rheumatism (EULAR). According to the
EULAR definition, patients are classified as good, moder-
ate, or non-responders, using the individual amount of
change in the DAS28 (DDAS28) and DAS28 values at
6 months. A good responder is classified if DDAS28 C 1.2
and DAS28 at 3 or 6 months B3.2; moderate responders
are patients with (DDAS28 C 1.2 and DAS28 at 3 or
6 months B5.1 and [3.2) or (0.6\DDAS28 B 1.2 and
DAS28 at 3 or 6 months B5.1). Patients are classified as
non-responders if they do not fall into any of these cate-
gories. Moreover, in some analyses, a comparison was
made between patients who had a good or moderate re-
sponse (subgroup I) and patients with no response
(subgroup II) which was due to the limited number of
patients in each group.
Safety of MTX therapy was analyzed on the basis of
medical history, physical examination, and selected
laboratory tests [including blood cell count, aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
creatinine, urea levels, and urinalysis]. The clinical and
laboratory tests were completed before the start of the
therapy and in months 2, 4 and 6 of the follow-up. The
concentrations of modulators of bone metabolism (OPG,
RANKL, Dkk-1 and sclerostin) were determined at base-
line and after 6 months. Designations were performed by
ELISA using kits: OPG (DRG Instruments GmbH, Ger-
many), sRANKL (DRG Instruments GmbH, Germany),
sclerostin (TECOmedical Group, Switzerland), human
Dkk-1 (Assay Design Inc., USA). The patients’ charac-
teristics are presented in Table 1. All the patients provided
written informed consent. The study was approved by the
Wroclaw Medical University Ethics Committee.
The control group consisted of 12 healthy women aged
41–73 (mean age 56.9, SD 11.06, median 56). Seventy-five
Table 1 Characteristics of
rheumatoid arthritis (RA)
patients at baseline and after
6 months of MTX therapy
Baseline After 6 months of MTX therapy
RA patients (n) 27 27
Females (%) 100 100
Age, mean (range) 54.7 (30–74)
Disease duration (years), mean (range) 4.75 (0.25–12)
Disease activity score DAS28, mean (range) 6.0 (4.9–7.9) 4.5 (3.2–6.4)
Tender joint count, mean (range) 12 (4–26) 6 (1–16)
Swollen joint count, mean (range) 7 (3–13) 3 (0–10)
Erythrocyte sedimentation rate (mm/h), mean (range) 48 (16–94) 35 (12–78)
Patient pain (mm), mean (range) 63 (27–85) 41 (12–70)
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percent of women in the control group were
postmenopausal.
The compared groups of women (study and control)
were consistent in relation to age, which was verified with
the parametric Student’s t test following normality check
with the Shapiro–Wilk test.
Statistical Analysis
The results are presented as mean ± SD. Normality of
distribution was verified with Shapiro–Wilk normality test.
If normal distribution was proofed, the comparison of the
groups was performed with parametric Student’s t test. If
the distribution of markers was significantly different from
normal distribution, a non-parametric Mann–Whitney
U test was used for comparison. When comparing the re-
sults before and after treatment tests for dependent
observations were used. In case of normally distributed
variables Student’s t test was applied. In other cases dif-
ferences were check with a non-parametric sign test. The
results were treated as significant if p value was less than
0.05. The statistical analysis was performed with Statistica.
Results
Comparative Analysis of Bone Metabolism
Regulator Concentrations in RA and Control Group
In the current study, the following differences were sta-
tistically significant in RA patients before starting on
MTX:
• higher RANKL concentrations compared to control
group (644.97 ± 477.13 vs. 255.19 ± 130.26 pmol/l,
respectively; p = 0.003) (Fig. 1),
• lower values of OPG/RANKL ratio compared to control
group (0.01124 ± 0.0101 vs. 0.01885 ± 0.0078, respec-
tively; p = 0.007) (Fig. 2),
• higher concentration of Dkk-1 compared to control
group (1821.32 ± 1060.28 vs. 548.52 ± 36.35 pg/ml,
respectively; p = 0.0003) (Fig. 3).
Osteoprotegerin levels and sclerostin levels, however,
were similar in both groups (OPG 4.17 ± 1.62 vs.
4.13 ± 0.93 pmol/l, sclerostin 0.40 ± 0.26 vs.
0.35 ± 0.17 ng/ml, respectively, p[ 0.05).
Assessment of Bone Metabolism Regulator
Concentrations in RA Patients During MTX
Therapy
In the analyzed group of patients after 6 months of therapy,
a statistically significant increase in the ratio of OPG/
RANKL was observed (0.0118 ± 0.0102 vs. 0.0141 ±
0.0118; p = 0.02) (Fig. 4). Concentrations of RANKL
(644.97 ± 477.13 vs. 526.32 ± 378.95 pmol/l), sclerostin
(0.40 ± 0.26 vs. 0.38 ± 0.26 ng/ml) and Dkk-1 (1821.32 ±
1060.28 vs. 1954.85 ± 1002.32 pg/l) did not change
significantly.
Assessment of Bone Metabolism Regulator
Concentrations in RA Patients in Relation
to Response to MTX Therapy
The study group of RA patients was subdivided in relation
to response to treatment (subgroup I—good or moderate
response, subgroup II—no response). Subgroup I consisted
of 20 patients (14 patients with good improvement, 6
Fig. 1 Comparison of RANKL levels between RA and control group.
Higher RANKL concentrations compared to control group
(p = 0.003)
Fig. 2 Comparison OPG/RANKL ratio between RA and control
group. Lower values of OPG/RANKL ratio compared to control
group (p = 0.007)
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patients with moderate improvement) and subgroup II—7
patients with no improvement.
In the present study, the mean concentration of RANKL
in the subgroup of improvement (subgroup I) decreased
after 6 months of treatment with MTX (601.01 ± 486.48
vs. 401.15 ± 233.42 pmol/l), and in the subgroup with no
improvement (subgroup II) increased (770.55 ± 460.66 vs.
801.45 ± 557.79 pmol/l). There was found a statistically
significant difference between mean values of the con-
centrations of RANKL between subgroups I and II after
treatment with MTX (401.15 ± 233.42 vs.
801.45 ± 557.79 pmol/l; p = 0.004) (Fig. 5). In subgroup
I, there was a greater increase in mean concentration of
OPG than in subgroup II (0.27 ± 0.73 vs. 0.04 ± 1.15 p-
mol/l), but this difference was not statistically significant.
Before starting treatment with MTX, the ratio of OPG/
RANKL was comparable between subgroups I and II
(0.01267 ± 0.01118 vs. 0.00716 ± 0.00402). However,
the value of the ratio of OPG/RANKL after treatment with
MTX between subgroups I and II differed significantly
(0.01702 ± 0.01274 vs. 0.00675 ± 0.00289; p = 0.03).
The difference in the mean concentrations of Dkk-1 before
and after treatment with MTX between subgroups I and II
was statistically significant (p = 0.002) (Fig. 6). In sub-
group I, mean concentration of Dkk-1 decreased after
6 months of treatment with MTX (2054.72 ± 1004.74 vs.
1831.70 ± 851.70 pg/ml); while in subgroup II, the mean
concentration of Dkk-1 increased (1214.48 ± 738.32 vs.
2275.01 ± 1385.23 pg/ml). There were no statistically
significant changes in the mean sclerostin concentrations
before and after treatment in subgroup I (0.43 ± 0.29 vs.
0.32 ± 0.12 ng/ml) or subgroup II (0.41 ± 0.28 vs.
0.32 ± 0.09 ng/ml).
Assessment of Bone Metabolism Regulator
Concentrations in RA Patients Depending
on the Severity of Bone Lesions According
to the Steinbrocker Classification
The study group of RA patients was subdivided in relation
to the Steinbrocker classification. In the group of patients
with grades I and II changes (combined group) in the
Steinbrocker classification compared to patients with
grades III and IV changes (combined group), we found no
statistically significant difference in the concentrations of
RANKL, OPG, Dkk-1, sclerostin, or ratio of OPG/
RANKL.
Fig. 3 Comparison concentration of Dkk-1 between RA and control
group. Higher concentration of Dkk-1 compared to control group
(p\ 0.001)
Fig. 4 Comparison of the ratio of OPG/RANKL in patients with RA
before (OPG/RANKL 1) and after (OPG/RANKL 2) treatment with
MTX. After 6 months of therapy, a statistically significant increase in
the ratio of OPG/RANKL was observed (p = 0.02)
Fig. 5 Comparison of the level of RANKL in patients with
improvement (subgroup I) and patients with no improvement
(subgroup II) after 6 months of treatment with methotrexate. There
was found a statistically significant difference between mean values
of the concentrations of RANKL between subgroups I and II after
treatment with MTX (p\ 0.05)
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This concerned both before (respectively, RANKL
572.36 ± 433.45 vs. 767.31 ± 544.48 pmol/l, OPG 4.34 ±
1.56 vs. 3.88 ± 1.77 pmol/l, Dkk-1 2016.57 ± 1172.80 vs.
1514.51 ± 844.44 pg/ml, sclerostin 0.41 ± 0.28 vs.
0.39 ± 0.22 ng/ml, OPG/RANKL 0.01 ± 0.01 vs.
0.01 ± 0.01) and after treatment (respectively, RANKL
531.36 ± 464.41 vs. 481.00 ± 209.43 pmol/l, OPG
4.68 ± 1.69 vs. 4.26 ± 1.80 pmol/l, Dkk-1 2153.53 ±
1161.09 vs. 1642.63 ± 643.03 pg/ml, sclerostin 0.43 ± 0.26
vs. 0.36 ± 0.22 ng/ml, OPG/RANKL 0.02 ± 0.01 vs.
0.01 ± 0.01). In any case, the p value does not exceed the
predetermined level of significance 0.05.
Discussion
Osteoclasts originate from the monocyte–macrophage lin-
eage under modulation of cytokines: macrophage colony-
stimulating factor (M-CSF) and RANKL (Maeda et al.
2013). M-CSF modulates proliferation, differentiation and
fusion of precursors and at later differentiation stages bone
resorbing activity (Braun and Zwerina 2011). RANKL is a
key mediator in differentiation, fusion and activation of
osteoclasts (Krys´kiewicz and Lorenc 2010; Nemeth et al.
2011). The connection of RANKL with the RANK sti-
mulates osteoclastogenesis. On the other hand, binding of
RANKL with OPG, which is a soluble competitive recep-
tor, inhibits osteoclast maturation (Kmiec´ and Sokołowska
2007; Krys´kiewicz and Lorenc 2006).
In RA patients, bone metabolism disorders occur. Bone
resorption is increased. Enhanced proliferation and activity
of osteoclasts cause bone erosions and bone mass loss.
Physiologically, RANKL is synthesized by osteoblasts and
stromal cells. In inflammatory conditions, under presence
of cytokines (TNF-a, IL-1), it can also be synthesized by T
cells, fibroblasts, synoviocytes, monocytes/macrophages
and activated B cells (Gravallese et al. 2000; Kmiec´ and
Sokołowska 2007). In the current study, higher serum
RANKL and a lower OPG/RANKL ratio were found in RA
patients compared to control subjects. This is consistent
with results obtained by other authors (Ellabban et al.
2012; Skoumal et al. 2005; Xu et al. 2012).
Osteoblasts participate in bone formation. Proliferation,
function and apoptosis of osteoblasts are regulated by the
Wnt/b-catenin pathway. Wnt family protein is a ligand for
a Frizzled receptor and triggers it resulting in stabilization
of the signal transduction proteins responsible for key gene
expression, that is, b-catenin (Pawlak-Bus´ and Leszczyn´ski
2011). Natural inhibitors of the Wnt/b-catenin pathway are
Dkk-1 and sclerostin (Goldring et al. 2013).
Dkk-1 protein inhibits bone formation (Goldring et al.
2013). It also has an impact on the severity of the process
of bone resorption (Diarra et al. 2007). TNF-a induced
Dkk-1 expression on synovial fibroblasts (Diarra et al.
2007; Goldring et al. 2013). Local production of Dkk-1 in
synovial membrane is related to its serum level increase
(Diarra et al. 2007). In the current study, statistically sig-
nificantly higher levels of Dkk-1 were observed in patients
with RA compared to the control group. This is consistent
with the results obtained by Wang et al. (2011).
Still the MTX effect on bone metabolism is not entirely
clear. Literature data report a decrease or no change of
bone tissue resorption markers during MTX therapy. Tor-
ikai et al. (2006) found a decrease of N-terminal
crosslinked telopeptide of chain a of type I collagen, and El
Miedany et al. (1998) observed a decrease in
deoxypyridinoline (DPD) level during therapy. However,
Mianur et al. (2002) observed no statistically significant
changes of DPD levels in RA patients treated with MTX. In
the present study, there was an increase in the ratio of
OPG/RANKL after 6 months of treatment with MTX. The
index value of OPG/RANKL is an important factor in
regulating the severity of the process of bone resorption
(Haynes et al. 2001). Predominance of RANKL over OPG
increases bone resorption, while predominance of OPG
over RANKL reduces such activity (Krys´kiewicz and
Lorenc 2006).
In animal RA models, Dkk-1 inhibition by a specific
antibody targeted against it was associated with osteoge-
nesis improvement (Diarra et al. 2007; Goldring et al.
2013). El Miedany et al. (1998) found increased levels of
an osteogenesis marker (bone alkaline phosphatase) in RA
patients after 3 months of MTX therapy. In the present
study, no statistically significant change of Dkk-1 protein
level after MTX therapy was observed in the whole RA
Fig. 6 Comparison of the level of Dkk-1 in patients with improve-
ment (subgroup I) and patients with no improvement (subgroup II)
after 6 months of treatment with MTX. In subgroup I mean
concentration of Dkk-1 decreased after 6 months of treatment with
MTX, while in subgroup II the mean concentration of Dkk-1
increased (p\ 0.01)
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group. However, in patients with a good response to ther-
apy the Dkk-1 level decreased, and in patients with no
response it increased. Dkk-1 concentration in serum cor-
relates with disease activity (Diarra et al. 2007). Therefore,
effective therapy with MTX (15–25 mg/week) in RA pa-
tients appears to positively influence bone tissue
metabolism through disease activity control. Patients not
responding to therapy deserve particular attention, as they
require therapy intensification.
We are aware of the limitations of our study, which arise
from the small study group, observation of only women
mainly in the postmenopausal period and 50 % of patients
used prednisone in constant dose for at least 8 weeks be-
fore the start of the study and during the study. To confirm
the results, we plan to continue the studies on a larger
group of patients including also other groups of patients
with RA.
In conclusion, the results confirm the presence of dis-
orders of bone metabolism in patients with RA. The
administration of MTX affects the value of the ratio of
OPG/RANKL and concentration of Dkk-1. It is important
for inhibiting the progression of bone loss to have an ef-
fective therapy in RA patients, decreasing the inflammatory
activity. Particular attention should be paid to patients not
responding to treatment, who should receive intensified
therapy.
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